Apellis Pharmaceuticals (APLS) to Release Earnings on Tuesday

Apellis Pharmaceuticals (NASDAQ:APLS) is expected to announce its Q1 2025 earnings results before the market opens on Tuesday, May 6th. Analysts expect Apellis Pharmaceuticals to post earnings of ($0.35) per share and revenue of $197.61 million for the quarter.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its quarterly earnings data on Friday, February 28th. The company reported ($0.29) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.08. The firm had revenue of $212.50 million for the quarter, compared to analyst estimates of $197.92 million. Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The business’s quarterly revenue was up 45.2% compared to the same quarter last year. During the same period last year, the firm earned ($0.73) earnings per share. On average, analysts expect Apellis Pharmaceuticals to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Apellis Pharmaceuticals Trading Up 2.7 %

NASDAQ:APLS opened at $17.96 on Tuesday. The company has a debt-to-equity ratio of 1.91, a current ratio of 4.36 and a quick ratio of 3.73. Apellis Pharmaceuticals has a one year low of $16.98 and a one year high of $49.38. The company has a market cap of $2.26 billion, a PE ratio of -8.85 and a beta of 0.85. The firm has a 50-day moving average of $22.70 and a 200-day moving average of $27.66.

Analyst Ratings Changes

A number of analysts have commented on APLS shares. Scotiabank boosted their price objective on Apellis Pharmaceuticals from $30.00 to $31.00 and gave the stock a “sector perform” rating in a report on Wednesday, April 2nd. Royal Bank of Canada decreased their price target on Apellis Pharmaceuticals from $24.00 to $21.00 and set a “sector perform” rating for the company in a report on Monday, April 21st. HC Wainwright restated a “buy” rating and set a $57.00 price objective on shares of Apellis Pharmaceuticals in a research note on Monday, March 3rd. The Goldman Sachs Group reduced their target price on shares of Apellis Pharmaceuticals from $36.00 to $32.00 and set a “neutral” rating for the company in a research note on Monday, March 3rd. Finally, JPMorgan Chase & Co. raised their price target on shares of Apellis Pharmaceuticals from $50.00 to $54.00 and gave the company an “overweight” rating in a research report on Tuesday, March 4th. Eight research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $45.28.

Insider Buying and Selling at Apellis Pharmaceuticals

In related news, General Counsel David O. Watson sold 5,569 shares of the business’s stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $25.10, for a total value of $139,781.90. Following the sale, the general counsel now directly owns 138,730 shares in the company, valued at approximately $3,482,123. The trade was a 3.86 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Cedric Francois sold 2,824 shares of the stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $29.52, for a total transaction of $83,364.48. Following the transaction, the chief executive officer now owns 415,695 shares of the company’s stock, valued at $12,271,316.40. This represents a 0.67 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 11,005 shares of company stock valued at $299,037. Company insiders own 6.80% of the company’s stock.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).